Drug Resistance Updates

Papers
(The H4-Index of Drug Resistance Updates is 43. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Editorial Board330
Modulating undruggable targets to overcome cancer therapy resistance247
Editorial Board212
N6-methyladenosine modification of 3'tRF-AlaAGC impairs PD-1 blockade efficacy by promoting lactic acid accumulation in the tumor microenvironment of gastric carcinoma159
Molecular subtype changes after acquiring resistance to tarlatamab in small cell lung cancer155
Plasmid-borne tigecycline resistance gene tet(X4) in Salmonella enterica and Escherichia coli isolates from a pediatric patient with diarrhea133
PARP inhibition elicits NK cell-associated immune evasion via potentiating HLA-G expression in tumor132
Overexpression of ABCC1 and ABCG2 confers resistance to talazoparib, a poly (ADP-Ribose) polymerase inhibitor128
Novel nanomedicines to overcome cancer multidrug resistance119
Sciatic nerve stimulation enhances NK cell cytotoxicity through dopamine signaling and synergizes immunotherapy in triple-negative breast cancer95
Unraveling the secrets: Evolution of resistance mediated by membrane proteins95
New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects93
Exosomal circular RNAs: A chief culprit in cancer chemotherapy resistance93
Unveiling the resistance to therapies in pancreatic ductal adenocarcinoma93
Target-based drug design strategies to overcome resistance to antiviral agents: opportunities and challenges92
Evolution of RND efflux pumps in the development of a successful pathogen92
Collateral sensitivity between tetracyclines and aminoglycosides constrains resistance evolution in carbapenem-resistant Klebsiella pneumoniae90
Replacing the tropolonic methoxyl group of colchicine with methylamino increases tubulin binding affinity with improved therapeutic index and overcomes paclitaxel cross-resistance87
Point mutation P174L of the penA gene endowing ceftazidime resistance to Burkholderia pseudomallei in China86
Editorial Board86
Tyrosine phosphorylation-mediated YAP1-TFAP2A interactions coordinate transcription and trastuzumab resistance in HER2+ breast cancer82
Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine81
Network biology and artificial intelligence drive the understanding of the multidrug resistance phenotype in cancer75
The role of ABCC10/MRP7 in anti-cancer drug resistance and beyond73
Inhibition of SIRT7 overcomes sorafenib acquired resistance by suppressing ERK1/2 phosphorylation via the DDX3X-mediated NLRP3 inflammasome in hepatocellular carcinoma71
Treatment strategies and drug resistance mechanisms in adenocarcinoma of different organs69
Drug resistance mechanisms in dopamine agonist-resistant prolactin pituitary neuroendocrine tumors and exploration for new drugs69
Enzymatic bionanocatalysts for combating peri-implant biofilm infections by specific heat-amplified chemodynamic therapy and innate immunomodulation69
Targeting anoikis resistance as a strategy for cancer therapy65
TRIM29 facilitates gemcitabine resistance via MEK/ERK pathway and is modulated by circRPS29/miR-770–5p axis in PDAC59
Editorial Board57
Novel mobile colistin resistance gene mcr-4.9 in Vibrio cholerae from migratory birds56
Research progress on gene mutations and drug resistance in leukemia53
Heterogeneity of SOS response expression in clinical isolates of Escherichia coli influences adaptation to antimicrobial stress52
Clinical implications of germline variations for treatment outcome and drug resistance for small molecule kinase inhibitors in patients with non-small cell lung cancer52
Global population structure and genomic surveillance framework of carbapenem-resistant Salmonella enterica51
Framework nucleic acid-based nanoparticles enhance temozolomide sensitivity in glioblastoma50
Current therapy and drug resistance in metastatic castration-resistant prostate cancer50
Emergence of silent NDM-1 carbapenemase gene in carbapenem-susceptible Klebsiella pneumoniae: Clinical implications and epidemiological insights48
Inhibition of NF-κB signaling unveils novel strategies to overcome drug resistance in cancers48
Overcoming cancer chemotherapy resistance by the induction of ferroptosis46
PDPN positive CAFs contribute to HER2 positive breast cancer resistance to trastuzumab by inhibiting antibody-dependent NK cell-mediated cytotoxicity45
Organoid models of drug resistant gastric adenosquamous carcinoma: Recapitulating tumor features and refining precision treatment44
Editorial Board43
Editorial Board43
0.022492170333862